Herceptin, Trastuzumab Newswire (Page 9)

Comprehensive Real-Time News Feed for Herceptin, Trastuzumab (generic). (Page 9)

Results 161 - 180 of 704 in Herceptin, Trastuzumab (generic)

  1. Study Data from Razi Vaccine and Serum Research Institute Update Knowledge of Breast CancerRead the original story

    Apr 2, 2014 | Hispanic Business

    Intensification of antiproliferative activity of trastuzumab through construction of immunotoxins and nano-immunoconjugates is a promising approach for treatment of cancer."

    Comment?

  2. Researchers Submit Patent Application, 'Method and Apparatus for...Read the original story

    Apr 2, 2014 | Hispanic Business

    News editors obtained the following quote from the background information supplied by the inventors: "The present invention relates to a method and a kit for predicting a cytotoxic activity, in particular, an antibody-dependent cellular cytotoxic activity.

    Comment?

  3. Synthon Pharmaceuticals??'s Anti-HER2 ADC Frontrunner SYD985...Read the original story

    Apr 2, 2014 | BioSpace

    Synthon Biopharmaceuticals today announced the results of a head-to-head comparative program of its antibody-drug conjugate SYD985 with Roche's market leading anti-HER2 ADC, T-DM1 .

    Comment?

  4. Synthon's Anti-HER2 ADC Frontrunner SYD985 Outperforms Only Available HER2-targeting ADCRead the original story

    Apr 2, 2014 | Customer Interaction Solutions

    SYD985 is a HER2-targeting ADC based on trastuzumab and Synthon's proprietary cleavable linker-duocarmycin payload.

    Comment?

  5. aceuticals Approval Trends in 2013Read the original story w/Photo

    Apr 1, 2014 | Biopharm

    In 2013, 19 products containing new biopharmaceutical molecular entities were approved in the United States and/or the European Union .

    Comment?

  6. Report: Breast Cancer Treatment Will Become More Dynamic as Companies ...Read the original story

    Mar 28, 2014 | P&T Community

    Decision Resources Group, a health care research firm located in Burlington, Mass., finds that efficacy more than any other factors drives oncologists' prescribing of targeted therapies for breast cancer.

    Comment?

  7. Hormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2014Read the original story

    Mar 27, 2014 | PRWeb

    MarketResearch.com announces the addition of a new market research report to their product offering: Hormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2014 GlobalData's clinical trial report, "Hormone Refractory Breast Cancer Global Clinical Trials ... (more)

    Comment?

  8. State-of-the-state on genetic-based testing and treatment for breast cancer issued by researchersRead the original story

    Mar 27, 2014 | Medical News Today

    Dartmouth researchers at its Norris Cotton Cancer Center have compiled a review of the role that information gathered through genetic testing plays in the diagnosis and treatment of breast cancer .

    Comment?

  9. Dartmouth Cancer Researchers Issue...Read the original story w/Photo

    Mar 26, 2014 | RedOrbit

    Dartmouth researchers at its Norris Cotton Cancer Center have compiled a review of the role that information gathered through genetic testing plays in the diagnosis and treatment of breast cancer .

    Comment?

  10. Investigation Report on China Trastuzumab Market, 2009-2018Read the original story

    Mar 24, 2014 | Sys-Con Media

    Trastuzumab is a monoclonal antibody that interferes with the HER2/neu receptor.

    Comment?

  11. State-of-the-state on genetic-based testing, treatment for breast cancer revealedRead the original story w/Photo

    Mar 24, 2014 | Science Daily

    A review of the role that information gathered through genetic testing plays in the diagnosis and treatment of breast cancer has been conducted.

    Comment?

  12. Dartmouth Cancer Researchers Issue State-of-the -State on...Read the original story

    Mar 21, 2014 | Newswise

    Dartmouth researchers at its Norris Cotton Cancer Center have compiled a review of the role that information gathered through genetic testing plays in the diagnosis and treatment of breast cancer.

    Comment?

  13. Proteomic Advances Hold Promise for Precision MedicineRead the original story

    Mar 20, 2014 | The American Journal of Managed Care

    The patient's metastatic cancer has resisted the trastuzumab and chemotherapy you initially prescribed, and she's relying on you to devise lifesaving fallback treatment.

    Comment?

  14. Synta Announces Positive Interim Results ...Read the original story

    Mar 20, 2014 | The Financial Mirror

    Synta Pharmaceuticals Corp. today announced presentation of interim results from the ENCHANT-1 trial, a single-arm multi-center Phase 2 proof-of-concept study designed to evaluate ganetespib, the Company's lead drug candidate, administered as monotherapy for the treatment of metastatic breast cancer.

    Comment?

  15. Closing the global cancer divide- performance of breast cancer care...Read the original story

    Mar 20, 2014 | BioMed Central

    Gerard CC Lim , Emran N Aina , Soon K Cheah , Fuad Ismail , Gwo F Ho , Lye M Tho , Cheng H Yip , Nur A Taib , Kwang J Chong , Jayendran Dharmaratnam , Matin M Abdullah , Ahmad K Mohamed , Kean F Ho , Kananathan Ratnavelu , Kananathan M Lim , Kin W Leong , Ibrahim A Wahid and Teck O Lim Cancer is the leading cause of deaths in the world.

    Comment?

  16. Synta and QuantumLeap Healthcare Collaborative Announce Selection of...Read the original story

    Mar 19, 2014 | Hispanic Business

    I-SPY 2 is a standing phase 2 randomized, controlled, multicenter trial for women with newly diagnosed, locally advanced breast cancer that is designed to test whether adding investigational drugs to standard chemotherapy is better than standard chemotherapy alone in the neo-adjuvant setting .

    Comment?

  17. Galena Biopharma Reports Fourth Quarter and Year End 2013 ResultsRead the original story

    Mar 17, 2014 | Hispanic Business

    "The last year has been transformational for Galena as we progressed from a development stage company to a revenue-generating commercial organization with products and programs that span the entire cancer care spectrum, including five ongoing or planned mid-to-late stage clinical trials," said and Chief Executive Officer.

    Comment?

  18. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Mar 17, 2014 | Business Wire

    Alcoa Expands in Hungary to Meet Surging European Demand for its Latest Innovation in Lightweight, Durable, Low-Maintenance Truck Wheels )--Alcoa , the inventor and global leader of forged aluminum wheels, is investing US$13 million to expand its wheel manufacturing plant in... )--Research and Markets has announced the addition of the "South Korea ... (more)

    Comment?

  19. Research and Markets: Competitor Analysis: Her2 Antibodies -...Read the original story

    Mar 17, 2014 | Business Wire

    The present Competitive Intelligence Report about Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting Her2 for treatment of Her2 positive breast and gastric cancer.

    Comment?

  20. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.Read the original story

    Mar 16, 2014 | CiteULike

    Expert review of anticancer therapy , Vol. 11, No. 2. , pp. 263-275, doi:10.1586/era.10.226 HER2 amplification is seen in up to 20% of breast cancers and is associated with an aggressive phenotype.

    Comment?